{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:45:29Z","timestamp":1787010329262,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Somatostatin receptor\u2013targeted \u03b1-therapy using \u03b1-emitter\n                    <jats:sup>225<\/jats:sup>\n                    Ac-labeled somatostatin analogs has been suggested as a treatment option in advanced metastatic neuroendocrine tumors (NETs) failing treatment with \u03b2-emitters, such as\n                    <jats:sup>177<\/jats:sup>\n                    Lu or\n                    <jats:sup>90<\/jats:sup>\n                    Y. Thymus NETs are rare and usually more aggressive than other neuroendocrine tumor entities. We present here a case with \u03b2-radiation refractory metastatic thymus NET, who demonstrated an excellent therapy response (molecular and morphological remission, as well as significantly improved clinical symptoms) after\n                    <jats:sup>225<\/jats:sup>\n                    Ac-DOTATOC\u2013targeted \u03b1-therapy, without any adverse effects during the treatment or in the follow-up period.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000003792","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T01:10:01Z","timestamp":1625793001000},"page":"1030-1031","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["225Ac-DOTATOC\u2013Targeted Somatostatin Receptor \u03b1-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to \u03b2-Radiation"],"prefix":"10.1097","volume":"46","author":[{"given":"Jingjing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshad R.","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Clinic, Zentralklinik Bad Berka, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[{"name":"Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000494760","article-title":"Targeted alpha particle therapy for neuroendocrine tumours: the next generation of peptide receptor radionuclide therapy","volume":"108","year":"2019","journal-title":"Neuroendocrinology"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/RLU.0000000000002915","article-title":"Peptide receptor radionuclide therapy using 225Ac-DOTATOC achieves partial remission in a patient with progressive neuroendocrine liver metastases after repeated beta-emitter peptide receptor radionuclide therapy","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"S1448","DOI":"10.21037\/jtd.2017.02.02","article-title":"Neuroendocrine tumors of the thymus and mediastinum","volume":"9","year":"2017","journal-title":"J Thorac Dis"},{"issue":"Suppl","key":"bib5-20250621","first-page":"S17","article-title":"Neuroendocrine neoplasms of the mediastinum","volume":"115","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/SLA.0b013e3181dd4ec4","article-title":"Thymic neuroendocrine tumors: a SEER database analysis of 160 patients","volume":"251","year":"2010","journal-title":"Ann Surg"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/jlcr.3792","article-title":"Targeted alpha therapy with bismuth-213 and actinium-225: meeting future demand","volume":"62","year":"2019","journal-title":"J Labelled Comp Radiopharm"},{"key":"bib8-20250621","first-page":"404","article-title":"Targeted alpha therapy: current clinical applications","volume":"35","year":"2020","journal-title":"Cancer Biother Radiopharm"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.semnuclmed.2020.02.003","article-title":"Supply and clinical application of actinium-225 and bismuth-213","volume":"50","year":"2020","journal-title":"Semin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T16:04:46Z","timestamp":1750521886000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003792","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,8]]}}}